GlassScriptPhysician profile
Crystal Mcclain
NPI 1407586621
$3,024.26
in general payments reported to CMS, 2019-2025
22 companies · $1,523 in 2025
The $1,523 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $95.15 · 2023: $692 · 2024: $714 · 2025: $1,523.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,929.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,929.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,723.22 | 2023-2025 | |
| Lilly USA, LLC | $387.62 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Neurocrine Biosciences, INC. | $129.17 | 2022-2024 | Ingrezza |
| Phathom Pharmaceuticals, INC. | $118.70 | 2025 | Voquezna |
| E.R. Squibb & Sons, L.L.C. | $118.11 | 2025 | Cobenfy |
| Pfizer INC. | $83.54 | 2024-2025 | |
| Novo Nordisk INC | $71.98 | 2023-2025 | Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $65.44 | 2024-2025 | Caplyta |
| Lundbeck LLC | $54.76 | 2025 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $38.08 | 2023 | Farxiga |
| Exact Sciences Corporation | $34.09 | 2025 | The Cologuard Plus Collection Kit |
| Organon LLC | $26.59 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $22.00 | 2022 | |
| Jazz Pharmaceuticals INC. | $19.75 | 2025 | |
| Xeris Pharmaceuticals, INC. | $18.93 | 2025 | Gvoke Hypopen |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acella Pharmaceuticals, LLC | $18.31 | 2025 | NP Thyroid 60 |
| Exeltis, USA INC. | $18.13 | 2025 | Slynd |
| Teva Pharmaceuticals USA, INC. | $16.07 | 2024 | Austedo Xr |
| Axsome Therapeutics, INC. | $15.84 | 2024 | Auvelity |
| Currax Pharmaceuticals LLC | $15.40 | 2025 | Contrave |
| Hologic Sales and Service, LLC | $14.61 | 2023 | Aptima |
| Avion Pharmaceuticals | $13.92 | 2023 | NP Thyroid 60 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Mcclain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.